Satellos Bioscience Inc. (MSCLF)
Market Closed
8 Apr, 20:00
OTC PINK OTC PINK Primary $
6. 25
+0.66
+11.8068%
$
96.62M Market Cap
- P/E Ratio
- Div Yield
62,399 Volume
-0.18 Eps
$ 5.59
Previous Close Want to track MSCLF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants.
Marketbeat | 1 month ago
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy
Toronto-based Satellos Bioscience is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases. Its lead drug candidate SAT-3247 is an oral pill, which aims to regenerate muscle function rather than merely delay its loss. Satellos has the potential to produce substantial rewards if SAT-3247 can demonstrate sufficient muscle regeneration in DMD patients in a safe and tolerable manner.
Seekingalpha | 11 months ago
